



ASX Announcement

31 May 2021

ASX Market Announcements
ASX Limited
Level 4
North Tower, Rialto
525 Collins Street
Melbourne VIC 3000

2021 Annual General Meeting Results

Melbourne, Australia, 31 May 2021 – In accordance with ASX Listing Rule 3.13.2 and section 251AA of the Corporations Act, Avecho Biotechnology Limited (ASX: AVE) advises that the details of the resolutions and the proxies received in respect of each resolution at its Annual General Meeting today are set out in the attached proxy summary.

For enquiries, please contact

Melanie Leydin
Company Secretary
+61 3 9692 7222

This announcement has been authorised by the Board of Directors of Avecho Biotechnology Limited.

About Avecho

Avecho Biotechnology Limited (ASX: AVE) develops and commercialises innovative Human and Animal Health products using its proprietary drug delivery system called TPM®. TPM® is derived from Vitamin E using unique, proprietary and patented processes and is proven to enhance the solubility and oral, dermal and transdermal absorption of drugs and nutrients.

Avecho's major projects include delivering TPM® enhanced injectable, oral and topical products for the human health market and is also developing TPM® to enhance the feed efficiency and health of livestock. New additions to the development program include the recently announced application of TPM® to cannabinoids.

See more here - avecho.com.au

**Annual General Meeting
Monday 31 May 2021
Voting Results**

The following information is provided in accordance with section 251AA(2) of Corporations Act 2001 (Cth)

Resolution Details				Show of Hands (S) or Poll (P)	Instructions given to validly appointed proxies (as at proxy close)				Number of votes cast on the poll (where applicable)			Resolution Result
Resolution		Resolution Type	If s259U applies		For	Against	Proxy's Discretion	Abstain	For	Against	Abstain	
1	Adoption of Remuneration Report	Ordinary	N/A	P	454,774,375 90.96%	30,774,184 6.15%	14,463,902 2.89%	1,944,041 -	485,238,277 93.99%	31,038,953 6.01%	1,944,041 -	Carried
2	Re-Election of Mr David Segal as a Director of the Company	Ordinary	N/A	N/A	This motion was withdrawn, as announced on 4 May 2021				This motion was withdrawn, as announced on 4 May 2021			N/A
3	Approval to Grant Options to Dr Gregory Collier (or his nominee)	Ordinary	N/A	P	399,447,090 79.62%	87,690,945 17.48%	14,552,369 2.90%	266,100 -	429,999,459 83.02%	87,955,714 16.98%	266,100 -	Carried
4	Approval to Grant Options to Mr David Segal (or his nominee)	Ordinary	N/A	N/A	This motion was withdrawn, as announced on 4 May 2021				This motion was withdrawn, as announced on 4 May 2021			N/A
5	Approval to Grant Options to Dr Ross Murdoch (or his nominee)	Ordinary	N/A	P	398,067,790 79.33%	89,066,979 17.75%	14,655,637 2.92%	166,100 -	428,723,427 82.76%	89,331,748 17.24%	166,100 -	Carried
6	Approval to Grant Options to Mr Matthew McNamara (or his nominee)	Ordinary	N/A	P	399,156,874 79.55%	88,081,164 17.55%	14,552,369 2.90%	166,100 -	429,709,243 82.95%	88,345,933 17.05%	166,100 -	Carried
7	Ratification of Prior Issue of Shares	Ordinary	N/A	P	196,216,503 86.17%	28,266,182 12.41%	3,244,482 1.42%	3,345,974 -	226,221,493 88.80%	28,530,951 11.20%	3,345,974 -	Carried
8	Ratification of Prior Issue of Options	Ordinary	N/A	P	195,780,831 85.59%	29,278,068 12.80%	3,681,982 1.61%	2,332,261 -	226,223,321 88.45%	29,542,837 11.55%	2,332,261 -	Carried
9	Ratification of Prior Issue of Broker Options	Ordinary	N/A	P	456,766,688 91.42%	28,305,286 5.66%	14,608,119 2.92%	2,276,417 -	498,135,315 94.58%	28,570,055 5.42%	2,276,417 -	Carried
10	Approval of 10% Placement Facility	Special	N/A	P	402,128,547 80.27%	84,186,251 16.80%	14,670,973 2.93%	970,740 -	443,560,028 84.01%	84,451,020 15.99%	970,740 -	Carried

*Votes cast by a person who abstains on an item are not counted in calculating the required majority on a poll.